PETACH TIKVA, Israel, Dec. 1, 2014 (GLOBE NEWSWIRE) -- Macrocure Ltd. (Nasdaq:MCUR), a clinical-stage biotechnology company focused on developing a novel therapeutic platform to address chronic and hard-to-heal wounds, today announced that at 8:35 AM ET on Thursday, December 11, 2014, Mr. Nissim Mashiach, Macrocure's President and Chief Executive Officer, will present at the Oppenheimer 25th Annual Healthcare Conference in New York City. Additional members of the Management Team will also attend and be available for one-on-one meetings.
To view a live webcast of the Company's presentation, please visit Macrocure's Investor Relations website at http://investor.macrocure.com under 'Events & Presentations'. The webcast will automatically be archived approximately three hours after the live event and will be available for 90 days through March 11, 2015.
About Macrocure Ltd.
Founded in 2008, Macrocure Ltd. is a clinical-stage biotechnology company focused on developing a novel therapeutic platform to address chronic and hard-to-heal wounds, such as DFUs and VLUs. The Company's novel approach is to treat and close chronic and other hard-to-heal wounds by injecting the human body's own wound healing and regenerative components directly into the wound itself.
CONTACT: Francesca M. DeMartino Investor Relations & Corporate Communications Macrocure Ltd. (310) 739-6476; email@example.com